SlideShare a Scribd company logo
1 of 23
type 2 diabetes and cardiovascular diseases
Professor / Mohammed Ahmed Bamashmos
Professor of Internal Medicine and Endocrinology
prevalence
risk factors
1- type 2 DM is one of major four independent risk factors of CVD
2- Diabetes and other associated CVD risk factors
- Glycemic variability
- Hypoglycemic complication
- Age and gender
- Hypertension
- Insulin resistance
- obesity
- Dyslipidemia
- Endothelial dysfunction
- inflammation
Pathogenesis of CVD in type 2 DM
1- type 2 diabetes and atherosclerotic
CVD
2- type 2 diabetes and HF
relation between DM and HF
3- type 2 diabetes and Arrhythmia
4- type 2 diabetes and hypertension
treatment ;
factors that should be considered ;
1- treatment target
2- tight glycemic control
3- Ovoid glycemic variability
4 – Ovoid hypoglycemic complication
5- Ovoid weight gain
6- treat diabetic dyslipidemia
7- reverse endothelial dysfunction
8- use drugs that have long term CV beneficial effect ( effect in reducing
MACE )
9- early use of Disease Diabetic Modifying drugs
1- treatment target
tight glycemic control
• Important ; ; any increase in HbA1C by 1 is associated with increased CV mortality by
11-16%
treat all CV risk factors in type 2
diabetes
1- Avoid hypoglycemia ;
adverse effect of hypoglycemia ;
- increased inflammation and CRP
- Endothelial dysfunction
- Sympatho adrenal response and increased adrenaline
2- use drugs that has effect in both FBS , PPBS and GV ;
adverse effect of GV ; endothelial dysfunction , thrombosis and increased
plaque instability
•
• 3- use GLDs that improve dyslipidemia and decrease BP
4- use GLDs that overcome endothelial dysfunction;
endothelial dysfunction leads to ;
- vasoconstriction , inflammation and thrombosis
5- use GLDs that decrease body weight ;
effect of weight gain ;
- insulin resistance
- hyperglycemia
- increased BP
- inflammation , dyslipidemia
- endothelial dysfunction
• 6- use GLDs that decrease IR
7 use GLDs that ;
- decrease inflammation
- decrease coagulation
8- Early use of diabetic diseases modifying drugs irrespective of
glycemic control as ( SGLT2I, GLP1RA , DPPT4I , and Metformin )
9- use GLDs that has beneficial effect in reducing MCVE (
new guideline
treatment of patients with established ASCVD or at
risk
patients with HF
type_2_diabetes_and_cardiovascular_diseases.pptx

More Related Content

Similar to type_2_diabetes_and_cardiovascular_diseases.pptx

Pharmacologic Management of Type 2 Diabetes.pdf
Pharmacologic Management of Type 2 Diabetes.pdfPharmacologic Management of Type 2 Diabetes.pdf
Pharmacologic Management of Type 2 Diabetes.pdf
yennykadwiayu
 
Diabetes and ramadan final publication
Diabetes and ramadan final publicationDiabetes and ramadan final publication
Diabetes and ramadan final publication
Hassan Tarig
 
5 DIABETES MELLITUS.power point presentation
5 DIABETES MELLITUS.power point presentation5 DIABETES MELLITUS.power point presentation
5 DIABETES MELLITUS.power point presentation
KelfalaHassanDawoh
 

Similar to type_2_diabetes_and_cardiovascular_diseases.pptx (20)

Diabetes and new anti diabetic drugs
Diabetes and new anti diabetic drugsDiabetes and new anti diabetic drugs
Diabetes and new anti diabetic drugs
 
Anti-Diabetics For Cardiac Patients The Proper Selection
Anti-Diabetics For Cardiac Patients The Proper SelectionAnti-Diabetics For Cardiac Patients The Proper Selection
Anti-Diabetics For Cardiac Patients The Proper Selection
 
12- DM for Undergraduate.ppt
12- DM for Undergraduate.ppt12- DM for Undergraduate.ppt
12- DM for Undergraduate.ppt
 
Pharmacologic Management of Type 2 Diabetes.pdf
Pharmacologic Management of Type 2 Diabetes.pdfPharmacologic Management of Type 2 Diabetes.pdf
Pharmacologic Management of Type 2 Diabetes.pdf
 
Oral anti diabetic drug
Oral anti diabetic drugOral anti diabetic drug
Oral anti diabetic drug
 
Type 2 Diabetes
Type 2 Diabetes Type 2 Diabetes
Type 2 Diabetes
 
After Metformin What- Indian Scenario
After Metformin What- Indian ScenarioAfter Metformin What- Indian Scenario
After Metformin What- Indian Scenario
 
Diabetes mellitus
Diabetes mellitusDiabetes mellitus
Diabetes mellitus
 
SAROGLITAZAR (LIPAGLYN)
SAROGLITAZAR (LIPAGLYN)SAROGLITAZAR (LIPAGLYN)
SAROGLITAZAR (LIPAGLYN)
 
Diagnosis and treatment of diabetes
Diagnosis and treatment of diabetesDiagnosis and treatment of diabetes
Diagnosis and treatment of diabetes
 
Diabetes and ramadan final publication
Diabetes and ramadan final publicationDiabetes and ramadan final publication
Diabetes and ramadan final publication
 
Impact of glucose lowering drugs on
Impact of glucose lowering drugs onImpact of glucose lowering drugs on
Impact of glucose lowering drugs on
 
diabetes mellitus by Tushar 202345.pptx
diabetes mellitus by Tushar 202345.pptxdiabetes mellitus by Tushar 202345.pptx
diabetes mellitus by Tushar 202345.pptx
 
DM Holistic Fam Med 2019
DM Holistic Fam Med 2019DM Holistic Fam Med 2019
DM Holistic Fam Med 2019
 
General medicine update for every doctor
General medicine update for every doctorGeneral medicine update for every doctor
General medicine update for every doctor
 
Current Management of Diabetes Mellitus by Ghaza khan.
Current Management of Diabetes Mellitus by Ghaza khan.Current Management of Diabetes Mellitus by Ghaza khan.
Current Management of Diabetes Mellitus by Ghaza khan.
 
Current management of Diabetes Mellitus by Ghaza khan.
Current management of Diabetes Mellitus by Ghaza khan.Current management of Diabetes Mellitus by Ghaza khan.
Current management of Diabetes Mellitus by Ghaza khan.
 
Hormones & related drugs 2.pdf
Hormones & related drugs 2.pdfHormones & related drugs 2.pdf
Hormones & related drugs 2.pdf
 
Presentation on co drug strategy for treating hypertension in type ii
Presentation on co drug strategy for treating hypertension in type iiPresentation on co drug strategy for treating hypertension in type ii
Presentation on co drug strategy for treating hypertension in type ii
 
5 DIABETES MELLITUS.power point presentation
5 DIABETES MELLITUS.power point presentation5 DIABETES MELLITUS.power point presentation
5 DIABETES MELLITUS.power point presentation
 

More from Faculty of Medicine And Health Sciences

More from Faculty of Medicine And Health Sciences (20)

c-peptide and chronic complication of diabetes mellitus
c-peptide and chronic complication of diabetes mellitusc-peptide and chronic complication of diabetes mellitus
c-peptide and chronic complication of diabetes mellitus
 
The prevalence of metabolic syndrome in Yemeni patients with hypothyroidism
The prevalence of metabolic syndrome in Yemeni patients with hypothyroidismThe prevalence of metabolic syndrome in Yemeni patients with hypothyroidism
The prevalence of metabolic syndrome in Yemeni patients with hypothyroidism
 
Diabetic nephropathy it's risk factors in Type-2 Diabeties
Diabetic nephropathy  it's risk factors in Type-2 DiabetiesDiabetic nephropathy  it's risk factors in Type-2 Diabeties
Diabetic nephropathy it's risk factors in Type-2 Diabeties
 
Cytokine_storm.types and their effect on the body organ
Cytokine_storm.types and their effect on the body organCytokine_storm.types and their effect on the body organ
Cytokine_storm.types and their effect on the body organ
 
Adrenal gland disorders.types ,diagnosis and treatment
Adrenal gland disorders.types ,diagnosis and treatmentAdrenal gland disorders.types ,diagnosis and treatment
Adrenal gland disorders.types ,diagnosis and treatment
 
acute kidney disease causes,diagnosis and treatment
acute kidney disease  causes,diagnosis and treatmentacute kidney disease  causes,diagnosis and treatment
acute kidney disease causes,diagnosis and treatment
 
Prevalence of abdominal obesity and its associated comorbid condition in adul...
Prevalence of abdominal obesity and its associated comorbid condition in adul...Prevalence of abdominal obesity and its associated comorbid condition in adul...
Prevalence of abdominal obesity and its associated comorbid condition in adul...
 
obesity_and_associated_medical_conditions_.pdf
obesity_and_associated_medical_conditions_.pdfobesity_and_associated_medical_conditions_.pdf
obesity_and_associated_medical_conditions_.pdf
 
Noval classification of diabetes mellitus.pptx
Noval classification of diabetes mellitus.pptxNoval classification of diabetes mellitus.pptx
Noval classification of diabetes mellitus.pptx
 
enteropathicarthritis diagnosis and treatment
enteropathicarthritis diagnosis and treatmententeropathicarthritis diagnosis and treatment
enteropathicarthritis diagnosis and treatment
 
gullian bare syndrome' diagnosis and treatment
gullian bare syndrome' diagnosis and treatmentgullian bare syndrome' diagnosis and treatment
gullian bare syndrome' diagnosis and treatment
 
diabetes and cardiovascular disease .pptx
diabetes and cardiovascular disease .pptxdiabetes and cardiovascular disease .pptx
diabetes and cardiovascular disease .pptx
 
cardiovascular outcome in trial of new antidiabetic drugs
cardiovascular outcome in trial of new antidiabetic drugscardiovascular outcome in trial of new antidiabetic drugs
cardiovascular outcome in trial of new antidiabetic drugs
 
Autoimmune disease .Types diagnosis and treatment
Autoimmune disease  .Types diagnosis and treatmentAutoimmune disease  .Types diagnosis and treatment
Autoimmune disease .Types diagnosis and treatment
 
.Inflammatory bowel disease type, diagnosis and treatment
.Inflammatory bowel disease type, diagnosis and treatment.Inflammatory bowel disease type, diagnosis and treatment
.Inflammatory bowel disease type, diagnosis and treatment
 
new_updated_treatment_of_type_2.pptx
new_updated_treatment_of_type_2.pptxnew_updated_treatment_of_type_2.pptx
new_updated_treatment_of_type_2.pptx
 
clinical-immunology.
clinical-immunology.clinical-immunology.
clinical-immunology.
 
Approach_to_rheumatology
Approach_to_rheumatologyApproach_to_rheumatology
Approach_to_rheumatology
 
protocol of management of hypothyroidism .pptx
protocol of management of hypothyroidism .pptxprotocol of management of hypothyroidism .pptx
protocol of management of hypothyroidism .pptx
 
obesity and associated medical complication.pptx
obesity and associated medical complication.pptxobesity and associated medical complication.pptx
obesity and associated medical complication.pptx
 

Recently uploaded

Neurulation and the formation of the neural tube
Neurulation and the formation of the neural tubeNeurulation and the formation of the neural tube
Neurulation and the formation of the neural tube
SaadHumayun7
 
會考英聽會考英聽會考英聽會考英聽會考英聽會考英聽會考英聽會考英聽會考英聽會考英聽
會考英聽會考英聽會考英聽會考英聽會考英聽會考英聽會考英聽會考英聽會考英聽會考英聽會考英聽會考英聽會考英聽會考英聽會考英聽會考英聽會考英聽會考英聽會考英聽會考英聽
會考英聽會考英聽會考英聽會考英聽會考英聽會考英聽會考英聽會考英聽會考英聽會考英聽
中 央社
 

Recently uploaded (20)

Championnat de France de Tennis de table/
Championnat de France de Tennis de table/Championnat de France de Tennis de table/
Championnat de France de Tennis de table/
 
Word Stress rules esl .pptx
Word Stress rules esl               .pptxWord Stress rules esl               .pptx
Word Stress rules esl .pptx
 
Operations Management - Book1.p - Dr. Abdulfatah A. Salem
Operations Management - Book1.p  - Dr. Abdulfatah A. SalemOperations Management - Book1.p  - Dr. Abdulfatah A. Salem
Operations Management - Book1.p - Dr. Abdulfatah A. Salem
 
REPRODUCTIVE TOXICITY STUDIE OF MALE AND FEMALEpptx
REPRODUCTIVE TOXICITY  STUDIE OF MALE AND FEMALEpptxREPRODUCTIVE TOXICITY  STUDIE OF MALE AND FEMALEpptx
REPRODUCTIVE TOXICITY STUDIE OF MALE AND FEMALEpptx
 
Dementia (Alzheimer & vasular dementia).
Dementia (Alzheimer & vasular dementia).Dementia (Alzheimer & vasular dementia).
Dementia (Alzheimer & vasular dementia).
 
How to Manage Notification Preferences in the Odoo 17
How to Manage Notification Preferences in the Odoo 17How to Manage Notification Preferences in the Odoo 17
How to Manage Notification Preferences in the Odoo 17
 
An Overview of the Odoo 17 Discuss App.pptx
An Overview of the Odoo 17 Discuss App.pptxAn Overview of the Odoo 17 Discuss App.pptx
An Overview of the Odoo 17 Discuss App.pptx
 
Capitol Tech Univ Doctoral Presentation -May 2024
Capitol Tech Univ Doctoral Presentation -May 2024Capitol Tech Univ Doctoral Presentation -May 2024
Capitol Tech Univ Doctoral Presentation -May 2024
 
[GDSC YCCE] Build with AI Online Presentation
[GDSC YCCE] Build with AI Online Presentation[GDSC YCCE] Build with AI Online Presentation
[GDSC YCCE] Build with AI Online Presentation
 
....................Muslim-Law notes.pdf
....................Muslim-Law notes.pdf....................Muslim-Law notes.pdf
....................Muslim-Law notes.pdf
 
The Ultimate Guide to Social Media Marketing in 2024.pdf
The Ultimate Guide to Social Media Marketing in 2024.pdfThe Ultimate Guide to Social Media Marketing in 2024.pdf
The Ultimate Guide to Social Media Marketing in 2024.pdf
 
The Benefits and Challenges of Open Educational Resources
The Benefits and Challenges of Open Educational ResourcesThe Benefits and Challenges of Open Educational Resources
The Benefits and Challenges of Open Educational Resources
 
Neurulation and the formation of the neural tube
Neurulation and the formation of the neural tubeNeurulation and the formation of the neural tube
Neurulation and the formation of the neural tube
 
“O BEIJO” EM ARTE .
“O BEIJO” EM ARTE                       .“O BEIJO” EM ARTE                       .
“O BEIJO” EM ARTE .
 
Basic Civil Engg Notes_Chapter-6_Environment Pollution & Engineering
Basic Civil Engg Notes_Chapter-6_Environment Pollution & EngineeringBasic Civil Engg Notes_Chapter-6_Environment Pollution & Engineering
Basic Civil Engg Notes_Chapter-6_Environment Pollution & Engineering
 
factors influencing drug absorption-final-2.pptx
factors influencing drug absorption-final-2.pptxfactors influencing drug absorption-final-2.pptx
factors influencing drug absorption-final-2.pptx
 
Morse OER Some Benefits and Challenges.pptx
Morse OER Some Benefits and Challenges.pptxMorse OER Some Benefits and Challenges.pptx
Morse OER Some Benefits and Challenges.pptx
 
MichaelStarkes_UncutGemsProjectSummary.pdf
MichaelStarkes_UncutGemsProjectSummary.pdfMichaelStarkes_UncutGemsProjectSummary.pdf
MichaelStarkes_UncutGemsProjectSummary.pdf
 
Pragya Champions Chalice 2024 Prelims & Finals Q/A set, General Quiz
Pragya Champions Chalice 2024 Prelims & Finals Q/A set, General QuizPragya Champions Chalice 2024 Prelims & Finals Q/A set, General Quiz
Pragya Champions Chalice 2024 Prelims & Finals Q/A set, General Quiz
 
會考英聽會考英聽會考英聽會考英聽會考英聽會考英聽會考英聽會考英聽會考英聽會考英聽
會考英聽會考英聽會考英聽會考英聽會考英聽會考英聽會考英聽會考英聽會考英聽會考英聽會考英聽會考英聽會考英聽會考英聽會考英聽會考英聽會考英聽會考英聽會考英聽會考英聽
會考英聽會考英聽會考英聽會考英聽會考英聽會考英聽會考英聽會考英聽會考英聽會考英聽
 

type_2_diabetes_and_cardiovascular_diseases.pptx

  • 1. type 2 diabetes and cardiovascular diseases Professor / Mohammed Ahmed Bamashmos Professor of Internal Medicine and Endocrinology
  • 3. risk factors 1- type 2 DM is one of major four independent risk factors of CVD 2- Diabetes and other associated CVD risk factors - Glycemic variability - Hypoglycemic complication - Age and gender - Hypertension - Insulin resistance - obesity - Dyslipidemia - Endothelial dysfunction - inflammation
  • 4. Pathogenesis of CVD in type 2 DM
  • 5. 1- type 2 diabetes and atherosclerotic CVD
  • 6. 2- type 2 diabetes and HF
  • 8. 3- type 2 diabetes and Arrhythmia
  • 9. 4- type 2 diabetes and hypertension
  • 10. treatment ; factors that should be considered ; 1- treatment target 2- tight glycemic control 3- Ovoid glycemic variability 4 – Ovoid hypoglycemic complication 5- Ovoid weight gain 6- treat diabetic dyslipidemia 7- reverse endothelial dysfunction 8- use drugs that have long term CV beneficial effect ( effect in reducing MACE ) 9- early use of Disease Diabetic Modifying drugs
  • 12. tight glycemic control • Important ; ; any increase in HbA1C by 1 is associated with increased CV mortality by 11-16%
  • 13. treat all CV risk factors in type 2 diabetes 1- Avoid hypoglycemia ; adverse effect of hypoglycemia ; - increased inflammation and CRP - Endothelial dysfunction - Sympatho adrenal response and increased adrenaline 2- use drugs that has effect in both FBS , PPBS and GV ; adverse effect of GV ; endothelial dysfunction , thrombosis and increased plaque instability
  • 14. • • 3- use GLDs that improve dyslipidemia and decrease BP 4- use GLDs that overcome endothelial dysfunction; endothelial dysfunction leads to ; - vasoconstriction , inflammation and thrombosis 5- use GLDs that decrease body weight ; effect of weight gain ; - insulin resistance - hyperglycemia - increased BP - inflammation , dyslipidemia - endothelial dysfunction
  • 15. • 6- use GLDs that decrease IR
  • 16. 7 use GLDs that ; - decrease inflammation - decrease coagulation 8- Early use of diabetic diseases modifying drugs irrespective of glycemic control as ( SGLT2I, GLP1RA , DPPT4I , and Metformin ) 9- use GLDs that has beneficial effect in reducing MCVE (
  • 17.
  • 18.
  • 20.
  • 21. treatment of patients with established ASCVD or at risk